Azacitidine combined with interferon‐α for pre‐emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study

Documenti analoghi

• Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS , limited in AML
  di: Dong Hyun Kim, et al.
  Pubblicazione: (2025)
• Comprehensive risk stratification for adult T‐cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation
  di: Fangfang Yu, et al.
  Pubblicazione: (2025)
• Clinical features and prognostic model for viral encephalitis after allogeneic haematopoietic stem cell transplantation
  di: Jin Wu, et al.
  Pubblicazione: (2024)
• Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation
  di: Xiaolu Zhu, et al.
  Pubblicazione: (2025)
• Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation
  di: Francesca Perutelli, et al.
  Pubblicazione: (2025)